ResearchBIORXIVToday
Wolfram syndrome is a rare genetic disorder that causes diabetes, vision loss, hearing loss, and brain problems. Researchers created a new scoring system that looks at the specific genetic mutations in the WFS1 gene to predict how severe a patient's symptoms will be and when they might appear. This system could help doctors understand what to expect for each patient based on their individual genetic makeup.
WHY IT MATTERSIf validated, this genotype-based scoring system could allow doctors to predict disease progression and symptom onset in individual Wolfram syndrome patients, enabling earlier intervention and personalized monitoring strategies.
Clinical trialCLINICALTRIALSToday
Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a Phase 2 trial, meaning the drug has already been tested in a small group and now researchers want to see if it works better and remains safe in a larger group of 66 patients. The study is currently accepting new participants.
WHY IT MATTERSIf you have metastatic or locally advanced non-small cell lung cancer with uncommon EGFR mutations, this trial offers access to a potentially new treatment option that may not yet be available outside of clinical research.
Clinical trialCLINICALTRIALSToday
Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will first figure out the right dose and watch for side effects, then test how well the drug works against the cancer. About 266 patients will participate across multiple hospitals.
WHY IT MATTERSThis trial is now actively recruiting patients with EGFR and/or HER2-mutated advanced NSCLC — if you have this genetic profile and have exhausted standard treatments, you may be eligible to access a potentially new treatment option.
ResearchRSS2 days ago
Scientists discovered that some people with ALS (a disease that affects nerve cells controlling muscles) may develop the condition from new mutations that happen by chance in their nerve cells, rather than inheriting the mutation from their parents. This is different from inherited ALS cases where a parent passes down a faulty gene. This finding suggests there are multiple ways ALS can develop, which could help doctors better understand and treat the disease.
WHY IT MATTERSIf your ALS diagnosis is sporadic (not inherited), this research suggests your condition may have developed from random mutations in your nerve cells rather than a genetic predisposition, which could change how doctors approach your treatment and genetic counseling.
Clinical trialCLINICALTRIALS3 days ago
Researchers are looking for patients with advanced lung cancer (stage III) that cannot be removed with surgery and has unusual genetic mutations. The study will test whether giving patients targeted drugs based on their specific genetic mutation, followed by surgery, works better than standard treatment. About 120 patients will participate in this research.
WHY IT MATTERSIf you have unresectable stage III NSCLC with a rare mutation, this trial offers access to personalized treatment tailored to your specific genetic profile before surgery—an approach not yet widely available outside research settings.
ResearchPUBMEDApr 16
Scientists created a new tool called STRIPE that uses advanced genetic testing to read long strands of RNA (the instructions cells use to make proteins). This tool can detect genetic mistakes that cause rare diseases by looking at how genes are actually working in cells, not just finding the mutations themselves. It's designed to be faster, cheaper, and more practical than older methods, which could help doctors diagnose rare genetic diseases that are hard to identify.
WHY IT MATTERSPatients with undiagnosed rare genetic diseases could finally get answers through more accurate genetic testing, since STRIPE can detect disease-causing variants that standard DNA tests might miss.
ResearchPUBMEDApr 14
Scientists have discovered that certain rare genetic diseases are caused by mutations in genes that help cells copy their DNA. These genes normally produce proteins that untangle special twisted DNA structures called G-quadruplexes that get in the way during copying. When these proteins don't work properly, cells can't copy their DNA correctly, leading to problems like weak immune systems, slow growth, birth defects, and increased cancer risk.
WHY IT MATTERSUnderstanding which genes cause these G-quadruplex problems could help doctors diagnose patients with unexplained immunodeficiency, growth delays, or birth defects, and may eventually lead to targeted treatments for these currently untreatable conditions.
ResearchBIORXIVApr 12
Scientists created animal models (using fish and mice) that mimic DeSanto-Shinawi Syndrome, a rare genetic disorder caused by mutations in the WAC gene. These animal models showed symptoms similar to what patients experience, including developmental delays, intellectual disability, autism-like behaviors, and seizures. This research helps scientists understand how WAC gene mutations cause these symptoms and could lead to better treatments in the future.
WHY IT MATTERSFor the first time, researchers have created animal models that reproduce the key symptoms of DeSanto-Shinawi Syndrome, which could accelerate the discovery of why patients develop autism, seizures, and developmental delays—and potentially identify new treatment targets.
Clinical trialCLINICALTRIALSApr 6
Researchers are testing a new drug called zipalertinib to see if it helps people with early-stage lung cancer that has specific genetic mutations. Patients who had surgery to remove their tumors will receive either the new drug or a placebo (fake medicine) along with standard chemotherapy. The study wants to find out if zipalertinib can prevent the cancer from coming back better than chemotherapy alone.
WHY IT MATTERSIf you have early-stage NSCLC with uncommon EGFR mutations (like exon 20 insertions) and recently had surgery, this trial offers access to a targeted therapy specifically designed for your mutation type before it becomes widely available.
Clinical trialUNITERAREApr 5
Researchers are testing a new cancer treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack their specific cancer, and then puts them back into the body. This Phase 1 trial is for people with blood cancers like leukemia and lymphoma. The treatment is personalized—each patient's cells are customized based on their individual cancer's unique mutations.
WHY IT MATTERSThis trial offers patients with hematologic malignancies access to a cutting-edge personalized immunotherapy that targets their cancer's unique mutations, potentially offering a new treatment option for those who may have limited alternatives.
Clinical trialUNITERAREApr 3
Researchers are testing a new experimental drug called EPI-326 in people with two types of cancer: non-small cell lung cancer and head and neck cancer, both caused by mutations in the EGFR gene. This is an early-stage study (Phase 1) to see if the drug is safe and how much patients can tolerate. The study is currently accepting new participants and is expected to start in April 2026.
WHY IT MATTERSThis trial offers access to a novel EGFR-targeted therapy for patients with EGFR-mutant lung or head and neck cancers who may have limited treatment options or resistance to current therapies.
ResearchBIORXIVApr 2
Researchers discovered that mutations in a gene called THAP12 cause a severe type of childhood epilepsy called developmental and epileptic encephalopathy. Two siblings with this condition had two broken copies of the THAP12 gene (one from each parent), which stopped the gene from making enough of its protein. This finding helps explain why some children develop severe seizures early in life and could lead to better diagnosis and treatment options.
WHY IT MATTERSFamilies with children diagnosed with infantile spasms or Lennox-Gastaut syndrome now have a new genetic cause to test for, which could explain their child's condition and guide future treatment decisions.
ResearchPUBMEDMar 28
Scientists are studying a new way to treat corneal scarring (clouding of the eye that causes blindness) using tiny particles called extracellular vesicles that come from immune cells called macrophages. This approach is being tested for rare genetic eye diseases like epidermolysis bullosa, KID syndrome, and aniridia, where the cornea becomes scarred due to chronic inflammation and genetic mutations. Current treatments don't work well and have significant side effects, so this new method could offer patients a better option.
WHY IT MATTERSFor patients with epidermolysis bullosa, KID syndrome, or aniridia experiencing corneal scarring, this research offers a potential new treatment strategy that could prevent blindness without the side effects of current therapies.
ResearchPUBMEDMar 28
Scientists are getting better at finding rare genetic diseases using a tool called next-generation sequencing, which can read a person's DNA quickly and accurately. They're also developing new medicines called antisense oligonucleotides that can be customized for each patient to fix problems caused by genetic mutations. Together, these advances mean doctors can diagnose rare diseases faster and create personalized treatments tailored to each person's specific genetic makeup.
WHY IT MATTERSThis research shows a clear path for patients with rare genetic diseases to move from diagnosis to personalized treatment within a single medical framework, potentially reducing the diagnostic odyssey that currently takes years for many rare disease patients.